Breast Implants Lymphoma Cancer
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The Law Offices of Thomas J. Lamb represents people who have been harmed by unsafe medical products, including cases involving breast implants associated with lymphoma.
In more detail, the US Food and Drug Administration (FDA) has received reports about women who have had breast implant procedures done and, later, were diagnosed with these medical conditions:
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
- Anaplastic Large Cell Lymphoma (ALCL)
- Non-Hodgkin Lymphoma (also known as Non-Hodgkin’s Lymphoma, NHL, or just Lymphoma)
- T-cell Lymphoma
Free Case Evaluation
We encourage you to submit a Breast Implants Cancer Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible breast implants case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
More Information
- Summary of Information
- The Disease
- FDA Information
- Resources
- Frequently Asked Questions
➤ About the Disease
➤ Symptoms
➤ Risk Factors
➤ Treatment
➤ Prognosis
About Us
We are here to help the women and families who have experienced this unfortunate situation. We have successfully handled personal injury and wrongful death cases for people throughout the country.
Our firm does not put its clients into large class actions lawsuits. Rather, an individual lawsuit is filed for each case. There are no costs associated with having us review your possible breast implants case.
Be assured that the information you provide to our law firm is treated as strictly confidential. Submitting a case evaluation does not obligate you to hire our law firm.
Lastly, we want you to know that you will get a reply directly from attorney Tom Lamb no later than the next business day.
Most Recent Article on This Topic
Health Canada Breast Implant Safety Review Shows High Risk of BIA-ALCL with Textured Implants
A recent Health Canada safety advisory comes following an updated safety review of breast implants and the associated risk of BIA-ALCL. According to the April 6, 2022 Health Canada advisory “Advisory – Updated safety review of breast implants underscores the continuing importance of monitoring for cancer; increased risk with highly textured (macro-textured) implants“, the organization found there continues to be a high risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in highly textured implants in comparison to those with smooth implants.
To read more of this article, click below:
The Health Canada Breast Implant Safety Review
This April 2022 Health Canada advisory aimed at evaluating the BIA-ALCL risk level difference between smooth and textured breast implants.
According to the April 6, 2022 Health Canada advisory “Advisory – Updated safety review of breast implants underscores the continuing importance of monitoring for cancer; increased risk with highly textured (macro-textured) implants“:
The 2019 safety review found that the estimated risk of BIA-ALCL in Canada is significantly higher in individuals with macro-textured breast implants compared to micro-textured or smooth implants.
Furthermore, in response to these findings Health Canada has suspended Allergan’s Biocell breast implant licenses.
Additionally, the same article reports Canada is not the only country to notice these trends:
An increase in reported cases in Canada is consistent with trends seen in other countries, including the United States. Canadian and international data continue to indicate that the risk of BIA-ALCL is higher with macro-textured breast implants compared to breast implants with other surface textures (micro-textured and smooth).
Health Canada’s Recommendations for Next Steps
If you’re wondering where this leaves you in terms of next steps, Health Canada has a few recommendations. The organization is currently recommending implants only be removed if you have spoken with your healthcare provider and there are signs and symptoms of BIA-ALCL. According to the April 2022 Health Canada advisory:
[Read article in full at original source]While this information is concerning for people who have Allergan Biocell implants, preventive removal of breast implants is not recommended if there are no signs or symptoms suggestive of BIA-ALCL. Individuals who have, or who are considering breast implants, should speak to their healthcare provider about their benefits and risks.
Health Canada will continue to raise awareness of BIA-ALCL to support patient safety. The Department is launching a BIA-ALCL Canadian Surveillance Data Blog, and will continue to monitor and report new Canadian cases of BIA-ALCL. The Department also maintains detailed information on breast implants to support health professionals and people who have, or who are considering implants.
Health Canada will also continue to work with manufacturers to help support patient safety. To date, manufacturers have implemented comprehensive labelling changes, including adding strong warnings about the risk of BIA-ALCL, and patient decision checklists. Health Canada will also conduct yearly follow-ups with manufacturers.
Our earlier articles about this breast implants lymphoma cancer situation:
- FDA Sets New Regulations for Breast Implant Manufacturers
- BIA-ALCL Current Recommendations and Potential Future FDA Guidance Changes
- BIA-ALCL Case Studies Confirm Importance of Proper Treatment
- Black Box Warning Label Change for Breast Implants Finalized by the FDA
- New BIA-ALCL Cases Identified in Updated FDA Report
- Most American Women Are Unaware of BIA-ALCL
- Allergan Aesthetics Launches Tracking Campaign for U.S. Breast Implant Patients
- Advances Made in Understanding and Treatment of BIA-ALCL
- Cancer Linked to Breast Implants: Is it Considered Rare Anymore?
- FDA Proposes New Recommendations for Breast Implant Labels
- TGA Regulations on Breast Implant Products
- FDA Recalls Allergan Textured Implants
- Statistics Show An Increased Risk For BIA-ALCL With Textured Implants
- Textured Breast Implants Ban: Onto Australia
- FDA Fails When It Comes To Banning Textured Breast Implants
- Textured Breast Implants Bans on the Rise
- March 2019 FDA Meeting On Breast Implants: A Summary Of What You Need To Know
- Breast Implants FDA March 2019 Meeting: Lymphoma Cancer Was A Main Topic
- 2019 Discoveries and Warnings on Breast Implant-Associated Lymphoma
- Breast Implants Lymphoma Cancer Cases Update February 2019 – US & Canada
- Allergan Textured Breast Implants Recalled In Europe Due To BIA-ALCL
- FDA Provides Updated Number of Breast Implants Lymphoma Cancers
- New Data Released on Risk of Lymphoma Due to Breast Implants
- Breast Implant-Associated Lymphoma Diagnoses on the Rise
- What is the Risk of Death Due to Breast Implant-Associated Lymphoma?
- Treatments For Breast Implants Associated Lymphoma And Blood Cancer
- Breast Implants and Lymphoma: Who’s to Blame?
- Breast Implants Lymphoma Cancer: Diagnosis And Treatment Developments
- Breast Implant Lymphoma: Causes Uncertain, but Costs Undeniable
- March 2017 FDA Report: Breast Implants Linked To Lymphoma Blood Cancer
- Breast Implants Linked to Rare Lymphoma Blood Cancer